CytoSorbents (CTSO)
Develops blood-purification cartridges for critical care and cardiac surgery, commercializing CytoSorb internationally.
Something off on this page? Send us feedback.
Develops and commercializes blood-purification cartridges based on porous-polymer technology. CytoSorb is the flagship product, while ECOS-300CY and VetResQ are marketed and DrugSorb-ATR is advancing toward North American authorization.
Develops and commercializes blood-purification cartridges based on porous-polymer adsorbent technology for critical care and cardiac surgery. CytoSorb is the flagship product, alongside marketed ECOS-300CY and VetResQ, while CytoSorb XL and DrugSorb-ATR remain in development.
CytoSorb is CE-marked in the European Union and distributed in more than 70 countries. A New Jersey medical-device subsidiary handles research, development, and commercialization, while European, Indian, and Dubai subsidiaries conduct sales and marketing.
CytoSorb is not authorized, cleared, or approved in the United States. DrugSorb-ATR, for antithrombotic-drug removal in cardiothoracic surgery, remains investigational there; North American commercialization depends on resolving regulatory deficiencies and obtaining authorization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $26.3M · Total assets $38.0M · Shareholders' equity −$751.0K
- Revenue
- $9.6M
- Operating income
- −$2.6M
- Net income
- −$4.4M
No dividends on record.
| Institutions | 25.68% | 806.9K shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Insiders | 6.82% | 214.4K shares | |
| 6 holders · as of Sep 16, 2026 | |||
| Other | 67.50% | 2.12M shares | |
| remainder | |||
3.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Avenir CorpInstitution | 8.26% | 5.19M | as of Jun 30, 2026 |
Phillip P. ChanInsiderdirector, officer: Chief Executive Officer | 3.21% | 100,996 | filed Sep 16, 2026 |
Neuberger Berman Group LLCInstitution | 3.13% | 1.97M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.05% | 1.91M | as of Jun 30, 2026 |
CM Management, LLCInstitution | 2.35% | 1.48M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Phillip P. Chan | director, officer: Chief Executive Officer | +3,774 | $6.00 |
| Sep 15, 2026 | Alan D. Sobel | director | +2,500 | $6.10 |
| Sep 14, 2026 | Vincent Capponi | officer: President and COO | +2,073 | $6.05 |
| Sep 4, 2026 | Phillip P. Chan | director, officer: Chief Executive Officer | +200,000 | $0.3500 |
| Jun 15, 2026 | Peter J. Mariani | officer: Chief Financial Officer | +100,000 | $0.4400 |
- SeaStar Medical
Extracorporeal immunomodulation for sepsis-associated AKI
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytoSorbents | $5.02 | −5.64% | $16.7M | — | — | 0.4 | +0.2% |
| SeaStar Medical | $3.54 | +0.17% | $10.0M | — | — | 5.8 | +82.0% |
| Median | — | — | 5.8 | +82.0% |